Hero image
Image
![Medicines](sites/default/files/media/2020-06/2.2%20hero.jpg)
Pre heading
CHAPTER 2 - KEY FIGURES IN 2019
Human medicines
Assembly area
Heading
Rich text
EMA is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU. In 2019, EMA received a record number of requests for scientific advice. The numbers of applications for marketing authorisation were up again and EMA recommended 66 new medicines for marketing authorisation. EMA continued to closely monitor the safety of medicines on the market and take action when needed. The product information for 405 centrally authorised medicines was updated on the basis of new safety data. Here are some key figures on the authorisation and safety monitoring of medicines for human use in 2019. For more detailed information, download the full annual report 2019 (PDF version).
Heading
Rich text
SUPPORTING RESEARCH AND DEVELOPMENT
First column content
Image
![549 scientific advice requests received](sites/default/files/media/2020-06/HM-1%402x.png)
Second column content
Image
![57 PRIME recommendations adopted](sites/default/files/media/2020-06/HM-2%402x.png)
Heading
Rich text
RECOMMENDATIONS FOR MARKETING AUTHORISATION
First column content
Image
![117 applications for initial evaluation received](sites/default/files/media/2020-06/HM-3%402x.png)
Second column content
Image
![66 positive opinions - 12 withdrawn applications - 4 negative opinions](sites/default/files/media/2020-06/HM-4%402x.png)
Heading
Rich text
SAFETY MONITORING OF MEDICINES
First column content
Image
![2 million adverse drug reactions reported to EudraVigilance](sites/default/files/media/2020-06/HM-5-6%402x.png)
Second column content
Image
![1806 potential signals reviewed by EMA](sites/default/files/media/2020-06/HM-7%402x.png)